Leveraging a track record of 43,000 surgeries, CUREXO sets its sights on the U.S. joint-replacement market

[Financial News] CUREXO, having secured regulatory approvals in major markets for its knee joint-replacement surgical robot, has entered the U.S. market, bringing its hip robot to the market as well.
CUREXO said on the 9th that it took part in the ‘2026 Annual Meeting of the American Association of Hip and Knee Surgeons (AAHKS 2026 Annual Meeting),’ held in Dallas, Texas, from the 5th to the 8th (local time), and exhibited its joint-replacement surgical robot, ‘CUVIS-joint,’ and ‘CUVIS-joint THA,’ for total hip arthroplasty.
AAHKS is a leading professional association in hip and knee replacement, with around 5,000 members across 39 countries, including the United States and Canada. Its annual meeting draws large numbers of North American joint-replacement specialists and medical professionals each year.
The meeting was the first opportunity for CUREXO to showcase its product on a large scale to U.S. joint-replacement specialists after receiving 510(k) clearance for CUVIS-joint from the U.S. Food and Drug Administration (FDA) in March this year. CUREXO plans to use the event to expand its engagement with U.S. medical professionals and step up its entry into the local market.

CUVIS-joint is a fully automated joint-replacement surgical robot that uses a patient’s CT images to create a three-dimensional surgical plan and then precisely cuts bone according to that plan. Its open-platform design is not tied to any specific implant, allowing it to work with a range of implants and support personalized surgery.
After receiving approval from South Korea’s Ministry of Food and Drug Safety in 2020, the product went on to receive approval from Japan’s PMDA and CE MDR certification in Europe, before receiving U.S. FDA approval this year. It is now used in at least nine countries, with approximately 43,000 surgeries performed to date.

CUVIS-joint THA, also unveiled at the meeting, is a surgical robot for total hip arthroplasty. It is designed to minimize errors in implant placement and leg-length discrepancies by performing precise bone cuts based on a three-dimensional preoperative plan.
Last February, the first robotic hip replacement performed using a system from a South Korean medical robotics company was successfully completed, with Ha Yong-chan, director of Seoul Bumin Hospital, performing the surgery. CUREXO is currently pursuing regulatory approvals in North America and Europe.
A CUREXO spokesperson said, “This AAHKS participation was an opportunity to showcase CUVIS-joint’s technology and competitiveness in the U.S. market in earnest following FDA 510(k) clearance. Building on a track record of approximately 43,000 surgeries in global markets and our fully automated technology, we will highlight the competitiveness of our product portfolio spanning knees to hips and deliver tangible business results in the U.S. market.” 
[email protected] Jung Myung-jin, reporter